News

Press Releases

June 1, 2021
Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors
May 19, 2021
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
May 11, 2021
Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT
May 5, 2021
Verve Therapeutics Appoints Industry Leader Sheila Mikhail to its Board of Directors
See all

Media Contact
Gina Nugent
Ten Bridge Communications
(617) 460-3579
gina@tenbridgecommunications.com

Presentations and Publications

May 19, 2021
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Nature
January 12, 2021
Verve Therapeutics Corporate Presentation
39th Annual J.P. Morgan Healthcare Conference
June 27, 2020
Sekar Kathiresan, M.D., Keynote Presentation
International Society for Stem Cell Research Virtual 2020 Meeting
April 8, 2019
Genetics of Common, Complex Coronary Artery Disease
Cell
See all

Stay Connected

Find us on LinkedIn and Twitter